Increasing incidence of metastatic prostate cancer in the United States (2004–2013)

Weiner, Adam B.; Matulewicz, Richard S.; Eggener, Scott E.; Schaeffer, Edward M.

doi:10.1038/pcan.2016.30

Cited by 228 publications

(166 citation statements)

References 10 publications

Supporting

Mentioning

160

Contrasting

Unclassified

Order By: Relevance

“…23 To make sweeping recommendations based on the results of these few studies at face value will see us return to a time when a diagnosis of prostate cancer often had a much bleaker presentation and outcome. 24 The landscape of prostate cancer screening continues to be in flux. A 2017 revision of the USPSTF recommendations saw this group's stance against PSA screening soften, changing their rating from a 'D' to a 'C' grade.…”

Section: Discussionmentioning

confidence: 99%

Prostate-specific antigen testing for prostate cancer screening: A national survey of Canadian primary care physicians’ opinions and practices

Goldenberg¹,

Skeldon

Nayan

et al. 2017

CUAJ

View full text Add to dashboard Cite

Introduction: In 2014, the Canadian Task Force on Preventive Health Care (CTFPHC) recommended against routine prostate cancer screening with the prostate-specific antigen (PSA) blood test.1 We surveyed Canadian primary care physicians (PCPs) to understand their opinions and attitudes towards prostate cancer screening in 2016.Methods: Twenty PCPs piloted the survey to assess its accessibility. We distributed a flyer to 19 633 PCPs as an insert in a large mailed package inviting them to attend a national meeting, and later promoted the survey at the meeting. Multinomial logistic regression models examined factors associated with agreement of key guideline statements and the overall benefit of PSA screening.Results: A total of 1254 PCPs responded (rate of 6.4%); 54.7% of physicians aware of the CTFPHC recommendations report screening less often as a result. Overall, 55.6% of PCPs feel that the risks of PSA screening outweigh the benefits. On multivariable analysis, physicians who did not read the guidelines, did not have an academic appointment, or were in practice for over 20 years were significantly more likely to disagree with the statement that men 55‒69 years old should not be screened for prostate cancer with PSA.Conclusions: Our national survey found that the prostate cancer screening practices of Canadian PCPs varies widely across physician demographic groups, with almost equal numbers for or against. This has significant ethical, medical, and legal implications. The poor response rate to highly incentivized survey request may suggest a reluctance or general apathy towards this subject because of the Task Force recommendations. Future efforts should provide physicians with objective guidance around PSA screening, incorporating input from all stakeholders, including PCPs, urologists, and patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Prostate-specific antigen testing for prostate cancer screening: A national survey of Canadian primary care physicians’ opinions and practices

Goldenberg¹,

Skeldon

Nayan

et al. 2017

CUAJ

View full text Add to dashboard Cite

show abstract

“…80 Somewhat alarming is a recent report that the incidence of metastatic prostate cancer has increased by 72% since 2004. 95 Of particular concern is that the largest increase in new cases was…”

Section: Prostate Cancermentioning

confidence: 99%

Lifestyle Medicine: A Brief Review of Its Dramatic Impact on Health and Survival

Bodai¹,

Nakata²,

Wong

et al. 2018

TPJ

161

106

View full text Add to dashboard Cite

By ignoring the root causes of disease and neglecting to prioritize lifestyle measures for prevention, the medical community is placing people at harm. Advanced nations, influenced by a Western lifestyle, are in the midst of a health crisis, resulting largely from poor lifestyle choices. Epidemiologic, ecologic, and interventional studies have repeatedly indicated that most chronic illnesses, including cardiovascular disease, cancer, and type 2 diabetes, are the result of lifestyles fueled by poor nutrition and physical inactivity.In this article, we describe the practice of lifestyle medicine and its powerful effect on these modern instigators of premature disability and death. We address the economic benefits of prevention-based lifestyle medicine and its effect on our health care system: A system on the verge of bankruptcy. We recommend vital changes to a disastrous course. Many deaths and many causes of pain, suffering, and disability could be circumvented if the medical community could effectively implement and share the power of healthy lifestyle choices. We believe that lifestyle medicine should become the primary approach to the management of chronic conditions and, more importantly, their prevention. For future generations, for our own health, and for the Hippocratic Oath we swore to uphold ("First do no harm"), the medical community must take action. It is our hope that the information presented will inspire our colleagues to pursue lifestyle medicine research and incorporate such practices into their daily care of patients. The time to make this change is now.

show abstract

“…Such tumors are an infrequent case of death, and the men affected are more likely to die of other causes [8,9]. As a result, many men are subjected to unnecessary prostate biopsies and overtreatment of indolent cancer in order to save one man from dying of prostate cancer [8,9].…”

Section: Introductionmentioning

confidence: 99%

“…Almost 80% of cases are detected at clinically localized sage III, and more than half are expected to be low-risk tumors [7][8][9]. Such tumors are an infrequent case of death, and the men affected are more likely to die of other causes [8,9].…”

Section: Introductionmentioning

confidence: 99%

New developments in prostate cancer screening using a novel cancer-specific, non-PSA biomarker assay derived from autoantibody signatures

Hafron¹,

Yu²,

Juang³

et al. 2017

J Med Therap

View full text Add to dashboard Cite

show abstract

Increasing incidence of metastatic prostate cancer in the United States (2004–2013)

Cited by 228 publications

References 10 publications

Prostate-specific antigen testing for prostate cancer screening: A national survey of Canadian primary care physicians’ opinions and practices

Prostate-specific antigen testing for prostate cancer screening: A national survey of Canadian primary care physicians’ opinions and practices

Lifestyle Medicine: A Brief Review of Its Dramatic Impact on Health and Survival

New developments in prostate cancer screening using a novel cancer-specific, non-PSA biomarker assay derived from autoantibody signatures

Contact Info

Product

Resources

About